2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum Announces Plenary Sessions and Speakers, Including CIRM’s “Disease Team” Presentations

– October 20, 2011

WASHINGTON, DC, October 20, 2011 – The 2011 Stem Cell Meeting on the Mesa today announced further details of the agenda for its first Investor and Partnering Forum. In addition to more than 35 corporate presentations and six panels focused on the business of regenerative medicine, the California Institute for Regenerative Medicine (CIRM) will present research findings from six “Disease Teams” during the meeting. The CIRM disease teams presenting at the meeting are focused on developing stem cell-based therapies for brain tumors, type 1 diabetes, sickle cell disease, amyotrophic lateral sclerosis and HIV/AIDS.

The event will take place November 30-December 1, 2011 at the Sanford Consortium for Regenerative Medicine Building, La Jolla, California, and coincides with the Grand Opening of its new facility which brings together basic, translational and preclinical research teams from leading southern California research centers. For the first time, the Stem Cell Meeting on the Mesa’s agenda includes an investor and partnering forum, designed to showcase leading companies and clinical investigators in regenerative medicine. As previously announced, the first day of the meeting will showcase more than 35 corporate presentations.

2011 Presenting Companies and Institutions:

Aastrom Biosciences, Advanced BioHealing, Advanced Cell Technology, Aldagen, AlloSource, American Stem Cell, Athersys, bluebird bio, Cellerant Therapeutics, Cellular Dynamics International, City of Hope, Cytori Therapeutics, Fate Therapeutics, International Stem Cell Corporation, Juventas Therapeutics, Kiadis, Medipost, Medpace, MolMed S.p.A., Organogenesis, Organovo, Pervasis Therapeutics, Primorigen, Progenitor Cell Therapy, Proxy Biomedical, ReNeuron, Sangamo BioSciences, Sistemic, StemCells, Inc., Stanford University, TiGenix, Tissue Genesis, ViaCyte, UCLA, UCSD, Vet-Stem.

The Investor and Partnering forum will also include panels focused on business and regulatory topics with speakers from leading companies, government agencies and organizations. The discussion will begin with a plenary panel including:

  • Matthias Steger, Director of Business Development, Roche
  • Greg Lucier, CEO, Life Technologies Corporation
  • Mahendra Rao, Director, NIH Center for Regenerative Medicine
  • Susan L. Solomon, CEO, New York Stem Cell Foundation
  • Gil Van Bokkelen, CEO, Athersys, Inc and Chairman of the Alliance for Regenerative Medicine.
Additional panels include the following:
  • Building the Regulatory Pathway for RM.
  • Confronting the Translational Challenge.
  • Collaborative Models to Advance Early-Stage RM Programs.
  • Developing Sustainable and Scalable Business Models in RM.
  • Access to Finance: Industry Wide Issues.
  • Public and Private Pathways for Reimbursement.

The Investor and Partnering Forum is being organized  by the Sanford Consortium, CIRM and The Alliance for Regenerative Medicine (ARM) to facilitate translational research, promote engagement between the scientific and business communities and provide opportunities for business, academic research and investor participants to connect in one-on-one strategic partnering meetings.  Significant support is also provided by Roth Capital and CONNECT to attract leading life science investors.

To learn more or to register for the 2011 Stem Cell Meeting on the Mesa Symposium and Investor & Partnering Forum, please visit www.stemcellmeetingonthemesa.com.  Registration is complimentary for credentialed members of the media.

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, click here.